Biological Collection to Help Create Models for Digestive Cancers and IBD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study focuses on creating a biological collection from patients with IBD and various digestive cancers to develop translational preclinical models. The models use patient tissues and sera to study tumor ecosystems, screen candidate therapies, and predict responses to treatments in a personalized context. The approach aims to address limitations of animal models by using autologous materials to better reflect human disease biology. The study envisions ex vivo tumor modeling and therapy screening to advance understanding and therapeutic development for GI tract diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care.
* Diagnosed with digestive tract cancer on IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care.
* Diagnosed with digestive cancer (esophagus, stomach, colon/rectum) and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care.
* Diagnosed with Barrett's esophagus and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care

Exclusion Criteria:

* All other

Where it's running

• Hôpitaux Universitaires de Strasbourg
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Thomas BAUMERT
• Email: thomas.baumert@chru-strasbourg.fr
• Phone: 0033368853703

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effect of Periodontal Therapy on Gut Microbes and Inflammation in People with Inflammatory Bowel Disease

  This study tests whether treating gum disease in people with inflammatory bowel disease can influence the gut microbiome and markers of systemic inflammation.

  Recruiting University of Turin, Italy · Turin, Turin · NCT07905859

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Partial enteral nutrition to help IBD patients at nutritional risk maintain weight

  We’re testing whether adding an oral nutritional supplement (LH VIOLA) to standard counseling helps adults with IBD who are at risk of malnutrition keep or gain weight over 16 weeks.

  Recruiting at 4 sites Lionhealth Srl Società Benefit · Rozzano, Milano and 3 other locations · NCT07433946

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.